AffiliationCork Cancer Research Centre, Mercy University Hospital and Leslie C. Quick Jnr., Laboratory, University College Cork, Cork, Ireland.
MeSHCTLA-4 Antigen/antagonists & inhibitors
Forkhead Transcription Factors/antagonists & inhibitors
MetadataShow full item record
CitationCancer Res. 2011 Nov 15;71(22):6915-20. Epub 2011 Nov 8.
AbstractInfiltration of tumors by regulatory T cells confers growth and metastatic advantages by inhibiting antitumor immunity and by production of receptor activator of NF-kappaB (RANK) ligand, which may directly stimulate metastatic propagation of RANK-expressing cancer cells. Modulation of regulatory T cells can enhance the efficacy of cancer immunotherapy. Strategies include depletion, interference with function, inhibition of tumoral migration, and exploitation of T-cell plasticity. Problems with these strategies include a lack of specificity, resulting in depletion of antitumor effector T cells or global interruption of regulatory T cells, which may predispose to autoimmune diseases. Emerging technologies, such as RNA interference and tetramer-based targeting, may have the potential to improve selectivity and efficacy.
- Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
- Authors: Lozano T, Villanueva L, Durántez M, Gorraiz M, Ruiz M, Belsúe V, Riezu-Boj JI, Hervás-Stubbs S, Oyarzábal J, Bandukwala H, Lourenço AR, Coffer PJ, Sarobe P, Prieto J, Casares N, Lasarte JJ
- Issue date: 2015 Oct 1
- Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
- Authors: Saha A, Chatterjee SK
- Issue date: 2010 Feb
- Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity.
- Authors: Liu Y, Wang L, Predina J, Han R, Beier UH, Wang LC, Kapoor V, Bhatti TR, Akimova T, Singhal S, Brindle PK, Cole PA, Albelda SM, Hancock WW
- Issue date: 2013 Sep
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
- Authors: Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP
- Issue date: 2009 Aug 3
- Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
- Authors: Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G
- Issue date: 2012 May